Decoding the metabolic-immune axis for novel therapeutics in bladder cancer

Area of Science:

• Oncology
• Urology
• Cancer Biology

Background:

• Bladder cancer is a common urinary system malignancy, with urothelial carcinoma comprising over 90% of cases.
• Histologic subtypes include squamous cell carcinoma and adenocarcinoma, with papillary urothelial carcinoma being the most frequent.
• Genetic mutations (FGFR3, TP53) and epigenetic alterations (DNA hypermethylation, histone modification) are implicated in urothelial carcinoma development.

Purpose of the Study:

• To review the role of the metabolic-immune axis in bladder cancer progression and treatment resistance.
• To explore how tumor cell metabolic reprogramming and the immune suppressive tumor microenvironment interact.
• To establish a theoretical framework for future research directions in bladder cancer therapy.

Main Methods:

• Literature review focusing on the interplay between tumor metabolism and the tumor microenvironment.
• Analysis of mechanisms including enhanced glycolysis and altered amino acid/lipid metabolism.
• Synthesis of current research on targeted therapy, immunotherapy, and metabolic reprogramming in bladder cancer.

Main Results:

• The metabolic-immune axis significantly influences bladder cancer progression and response to treatment.
• Enhanced glycolysis and abnormal amino acid/lipid metabolism are key mechanisms.
• This axis presents a major challenge for overcoming drug resistance in advanced bladder cancer.

Conclusions:

• Understanding the metabolic-immune axis is crucial for developing novel bladder cancer treatments.
• Targeting metabolic reprogramming and the tumor microenvironment holds therapeutic potential.
• Further research is needed to translate these findings into effective clinical strategies.